HRP20050781B1 - Metode i farmaceutske mješavine za pouzdano postizanje prihvatljivih razina testosterona u serumu - Google Patents

Metode i farmaceutske mješavine za pouzdano postizanje prihvatljivih razina testosterona u serumu

Info

Publication number
HRP20050781B1
HRP20050781B1 HRP20050781AA HRP20050781A HRP20050781B1 HR P20050781 B1 HRP20050781 B1 HR P20050781B1 HR P20050781A A HRP20050781A A HR P20050781AA HR P20050781 A HRP20050781 A HR P20050781A HR P20050781 B1 HRP20050781 B1 HR P20050781B1
Authority
HR
Croatia
Prior art keywords
testosterone levels
serum
methods
pharmaceutical mixtures
mixtures
Prior art date
Application number
HRP20050781AA
Other languages
English (en)
Croatian (hr)
Inventor
Doris HÜBLER
Sabine Fricke
Jan-Peter Ingwersen
Wilhelm Kuhnz
Original Assignee
Bayer Intellectual Property Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32748728&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20050781(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Intellectual Property Gmbh filed Critical Bayer Intellectual Property Gmbh
Publication of HRP20050781A2 publication Critical patent/HRP20050781A2/hr
Publication of HRP20050781B1 publication Critical patent/HRP20050781B1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
HRP20050781AA 2003-03-14 2004-03-15 Metode i farmaceutske mješavine za pouzdano postizanje prihvatljivih razina testosterona u serumu HRP20050781B1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200300399 2003-03-14
PCT/IB2004/000716 WO2004080383A2 (en) 2003-03-14 2004-03-15 Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels

Publications (2)

Publication Number Publication Date
HRP20050781A2 HRP20050781A2 (en) 2005-10-31
HRP20050781B1 true HRP20050781B1 (hr) 2015-04-10

Family

ID=32748728

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20050781AA HRP20050781B1 (hr) 2003-03-14 2004-03-15 Metode i farmaceutske mješavine za pouzdano postizanje prihvatljivih razina testosterona u serumu

Country Status (39)

Country Link
US (2) US7718640B2 (OSRAM)
EP (2) EP1457208B9 (OSRAM)
JP (1) JP4680891B2 (OSRAM)
KR (2) KR20080096717A (OSRAM)
CN (2) CN101884639A (OSRAM)
AR (1) AR043603A1 (OSRAM)
AT (1) ATE336251T1 (OSRAM)
AU (1) AU2004218893B2 (OSRAM)
BR (2) BR122017008910A8 (OSRAM)
CA (1) CA2518910C (OSRAM)
CL (1) CL2004000527A1 (OSRAM)
CO (1) CO5700724A2 (OSRAM)
CR (1) CR7999A (OSRAM)
CY (1) CY1105794T1 (OSRAM)
DE (1) DE602004001893T2 (OSRAM)
DK (1) DK1457208T3 (OSRAM)
EA (1) EA011568B1 (OSRAM)
EC (1) ECSP056095A (OSRAM)
ES (1) ES2271772T3 (OSRAM)
HR (1) HRP20050781B1 (OSRAM)
IL (1) IL170473A (OSRAM)
IS (1) IS2565B (OSRAM)
JO (1) JO2505B1 (OSRAM)
ME (2) MEP14508A (OSRAM)
MX (1) MXPA04002395A (OSRAM)
NO (1) NO335179B1 (OSRAM)
NZ (1) NZ542321A (OSRAM)
PE (1) PE20041065A1 (OSRAM)
PL (1) PL1457208T3 (OSRAM)
PT (1) PT1457208E (OSRAM)
RS (1) RS51537B (OSRAM)
RU (2) RU2354381C2 (OSRAM)
SA (1) SA04250040B1 (OSRAM)
SI (1) SI1457208T1 (OSRAM)
TW (1) TWI345976B (OSRAM)
UA (1) UA82510C2 (OSRAM)
UY (1) UY28231A1 (OSRAM)
WO (1) WO2004080383A2 (OSRAM)
ZA (2) ZA200508313B (OSRAM)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050152858A1 (en) * 2003-07-11 2005-07-14 Isp Investments Inc. Solubilizing agents for active or functional organic compounds
WO2006113505A2 (en) 2005-04-15 2006-10-26 Clarus Therapeutics, Inc. Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
US8492369B2 (en) 2010-04-12 2013-07-23 Clarus Therapeutics Inc Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
GB0807605D0 (en) 2008-04-28 2008-06-04 Diurnal Ltd Lipid composition
AU2014200332B2 (en) * 2008-04-28 2016-10-06 Diurnal Limited Lipid composition
WO2010094623A1 (en) 2009-02-18 2010-08-26 Bayer Schering Pharma Aktiengesellschaft Formulation comprising drospirenone for subcutaneous or intramuscular administration
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
US20130178454A1 (en) * 2011-11-17 2013-07-11 Shalender Bhasin Combination of testosterone and ornithine decarboxylase (odc) inhibitors
EP2833944A4 (en) 2012-04-06 2016-05-25 Antares Pharma Inc ADMINISTRATION OF TESTOSTERONE COMPOSITIONS BY NEEDLE-SUPPORTED NOZZLE INJECTION
AR091006A1 (es) * 2012-05-09 2014-12-30 Univ Western Health Sciences Formulaciones de testosterona proliposomal
US20140171918A1 (en) * 2012-12-14 2014-06-19 Bioject, Inc. Use of a novel subcutaneous needle-free technique to deliver testosterone in hypogonadal men
PT2953667T (pt) * 2013-02-11 2020-01-28 Antares Pharma Inc Dispositivo de injeção a jato auxiliado por agulha tendo força de gatilho reduzida
TW201521731A (zh) * 2013-03-15 2015-06-16 利波辛股份有限公司 用於口服之脂平衡的長鏈睪固酮酯
EP3033138A4 (en) * 2013-08-12 2017-03-29 Nanomedical Systems Inc. Device and method for sustained release of low water solubility therapeutic agent in solubilizer
EA201692083A1 (ru) 2014-04-16 2017-03-31 Вейкс-Фарма Гмбх Фармацевтическая композиция для ветеринарии и ее применение
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
CN105056115A (zh) * 2015-08-05 2015-11-18 成都市飞龙水处理技术研究所 一种治疗化脓性睾丸炎的内服药物及其制备方法
US20180147215A1 (en) 2016-11-28 2018-05-31 Lipocine Inc. Oral testosterone undecanoate therapy
US11311554B2 (en) 2018-04-04 2022-04-26 Slayback Pharma Llc Pharmaceutical compositions of testosterone
US12150945B2 (en) 2018-07-20 2024-11-26 Lipocine Inc. Liver disease
KR102051808B1 (ko) * 2018-07-23 2019-12-04 주식회사 종근당 테스토스테론 운데카노에이트를 포함하는 안정한 약제학적 조성물
WO2020118437A1 (en) * 2018-12-14 2020-06-18 Acerus Biopharma Inc. Active ester derivatives of testosterone, compositions and uses thereof
US11564933B2 (en) 2019-04-12 2023-01-31 Tolmar, Inc. Methods of treating testosterone deficiency
EP4038147A4 (en) * 2019-10-03 2024-02-07 Caren Pharmaceuticals, Inc. COMBINATORIAL HORMONAL THERAPIES AND FORMULATIONS
CA3184810A1 (en) * 2020-06-11 2021-12-16 Ash Stevens, Llc Monomeric and oligomeric compound embodiments as contraceptives and therapies and methods of making and using the same
US12257257B2 (en) * 2023-07-27 2025-03-25 Lipocine, Inc. Testosterone dodecanoate compositions and methods
KR20250176964A (ko) * 2024-06-13 2025-12-22 주식회사 종근당 타다라필 또는 이의 약학적으로 허용가능한 염을 포함하는 주사용 조성물

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3164520A (en) * 1962-10-29 1965-01-05 Olin Mathieson Injectable steroid compositions containing at least 75% benzyl benzoate
US4212863A (en) * 1977-10-29 1980-07-15 Akzo N.V. Highly concentrated pharmaceutical formulations of steroids and processes for their preparation
WO1995012383A1 (en) * 1993-10-30 1995-05-11 Zhejiang Medical University An injectable solution of testosterone undecanoate
WO1997040823A1 (en) * 1996-04-26 1997-11-06 R.P. Scherer Limited Oral pharmaceutical compositions containing sex hormones
WO1998036770A1 (en) * 1997-02-24 1998-08-27 Cortendo Ab Preparations for the treatment of metabolic syndrome containing human growth hormone in combination with a cortisol synthesis inhibitor
WO2000059512A1 (en) * 1999-04-01 2000-10-12 Akzo Nobel N.V. Formulation comprising testosteron undecanoate and castor oil

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4181721A (en) 1975-10-27 1980-01-01 Schering Aktiengesellschaft Depot preparations in an oily, unsaturated solution for intramuscular injection
DE2548413A1 (de) 1975-10-27 1977-04-28 Schering Ag Depotpraeparate in oeliger ungesaettigter loesung zur intramuskulaeren injektion
GB1567515A (en) 1976-05-28 1980-05-14 Akzo Nv Esters of testo-sterone and 5 -dihydro-testosterone
US4242863A (en) * 1978-03-16 1981-01-06 Caterpillar Tractor Co. Dual phase fuel vaporizing combustor
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5364632A (en) 1989-04-05 1994-11-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Medicinal emulsions
KR100499438B1 (ko) * 1997-12-03 2005-07-07 머크 앤드 캄파니 인코포레이티드 수소화 피마자유를 함유하는 지속성 주사제
AU4513099A (en) 1998-06-19 2000-01-10 Akzo Nobel N.V. Cycloalkyl-carboxylic acid esters of 7.alpha.methyl-estr-4-en-3-one 17.beta.-ol (19-nor 7.alpha.-methyltestosterone)
RU2216546C2 (ru) 1998-06-19 2003-11-20 Акцо Нобель Н.В. СОЕДИНЕНИЕ (7α,17β)-7-МЕТИЛ-17-[(1-ОКСОУНДЕЦИЛ)ОКСИ]ЭСТР-4-ЕН-3-ОН, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, НАБОР ДЛЯ МУЖСКОЙ КОНТРАЦЕПЦИИ
HK1049442B (en) * 2000-02-15 2007-06-15 Bayer Schering Pharma Aktiengesellschaft Male contraceptive formulation comprising norethisterone and testosterone undecanoate
MXPA03001147A (es) 2000-08-23 2003-10-06 Akzo Nobel Nv Nueva formulacion de ester de testosterona para uso humano.

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3164520A (en) * 1962-10-29 1965-01-05 Olin Mathieson Injectable steroid compositions containing at least 75% benzyl benzoate
US4212863A (en) * 1977-10-29 1980-07-15 Akzo N.V. Highly concentrated pharmaceutical formulations of steroids and processes for their preparation
WO1995012383A1 (en) * 1993-10-30 1995-05-11 Zhejiang Medical University An injectable solution of testosterone undecanoate
WO1997040823A1 (en) * 1996-04-26 1997-11-06 R.P. Scherer Limited Oral pharmaceutical compositions containing sex hormones
WO1998036770A1 (en) * 1997-02-24 1998-08-27 Cortendo Ab Preparations for the treatment of metabolic syndrome containing human growth hormone in combination with a cortisol synthesis inhibitor
WO2000059512A1 (en) * 1999-04-01 2000-10-12 Akzo Nobel N.V. Formulation comprising testosteron undecanoate and castor oil

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch, Week 199524 Derwent Publications Ltd., London, GB; Class B01, AN 1995-185577 XP002264337 & WO9512383 A; UNIV ZHEJIANG MEDICAL 11. svibnja 1995 (11.05.1995.) *

Also Published As

Publication number Publication date
EA200501819A1 (ru) 2006-06-30
US20090156564A1 (en) 2009-06-18
RU2007118196A (ru) 2008-11-27
ME00149B (me) 2010-06-10
AU2004218893B2 (en) 2008-10-09
TWI345976B (en) 2011-08-01
SI1457208T1 (sl) 2007-02-28
AU2004218893A1 (en) 2004-09-23
ZA200508313B (en) 2007-04-25
EP1457208B1 (en) 2006-08-16
PE20041065A1 (es) 2005-02-24
JO2505B1 (en) 2009-10-05
WO2004080383B1 (en) 2005-05-06
UA82510C2 (uk) 2008-04-25
RS51537B (sr) 2011-06-30
NO20054711D0 (no) 2005-10-13
CN1761469A (zh) 2006-04-19
ATE336251T1 (de) 2006-09-15
US8338395B2 (en) 2012-12-25
KR20080096717A (ko) 2008-10-31
UY28231A1 (es) 2004-11-08
NZ542321A (en) 2008-05-30
AR043603A1 (es) 2005-08-03
HK1069325A1 (en) 2005-05-20
US20050032762A1 (en) 2005-02-10
US7718640B2 (en) 2010-05-18
IS2565B (is) 2009-12-15
PL1457208T3 (pl) 2007-01-31
RU2354381C2 (ru) 2009-05-10
TW200511997A (en) 2005-04-01
EP1457208B9 (en) 2006-10-25
CA2518910A1 (en) 2004-09-23
DK1457208T3 (da) 2006-12-11
BRPI0400214A8 (pt) 2023-05-09
MEP14508A (en) 2010-06-10
PT1457208E (pt) 2007-01-31
BRPI0400214A (pt) 2005-02-09
BR122017008910A8 (pt) 2023-05-09
KR100882378B1 (ko) 2009-02-05
WO2004080383A2 (en) 2004-09-23
IS8069A (is) 2005-10-12
CN101884639A (zh) 2010-11-17
CL2004000527A1 (es) 2005-02-18
CN1761469B (zh) 2019-05-17
SA04250040B1 (ar) 2008-01-07
WO2004080383A3 (en) 2005-03-31
EP1743646A3 (en) 2007-03-28
JP2006520377A (ja) 2006-09-07
JP4680891B2 (ja) 2011-05-11
BR122017008910A2 (OSRAM) 2005-02-09
ZA200700046B (en) 2008-04-30
ECSP056095A (es) 2006-03-01
NO20054711L (no) 2005-12-13
IL170473A (en) 2010-05-31
KR20050109561A (ko) 2005-11-21
CA2518910C (en) 2009-09-08
CY1105794T1 (el) 2011-02-02
HRP20050781A2 (en) 2005-10-31
DE602004001893T2 (de) 2007-03-15
EA011568B1 (ru) 2009-04-28
DE602004001893D1 (de) 2006-09-28
MXPA04002395A (es) 2004-09-20
CR7999A (es) 2006-05-29
NO335179B1 (no) 2014-10-13
EP1457208A1 (en) 2004-09-15
RU2005131724A (ru) 2006-05-10
RS20050702A (sr) 2007-06-04
ES2271772T3 (es) 2007-04-16
EP1743646A2 (en) 2007-01-17
CO5700724A2 (es) 2006-11-30

Similar Documents

Publication Publication Date Title
TW200511997A (en) Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels
EA200201000A1 (ru) Гормон-заместительная терапия
MXPA02011632A (es) Inhibidores de 11-beta-hidroxiesteroide deshidrogenasa tipo 1.
NO20042596L (no) Inbibitorer av 11-beta-hydroksy steroid dehydrogenase type 1
MXPA04004842A (es) Inhibidores de 11-(-hidroxiesteroide deshidrogenasa de tipo 1.
MXPA04004837A (es) Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1.
BR0001515A (pt) Composições de espuma estáveis
TW200609227A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
TN2009000137A1 (en) Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
AR023957A1 (es) Pirazol carboxamidas utiles para el tratamiento de la obesidad y otros trastornos.
IL153297A0 (en) Compounds and compositions for delivering active agents
WO2000072885A3 (en) Methods of inducing regulated pancreatic hormone production in non-pancreatic islet tissues
WO2007032962A3 (en) Compositions and methods for intranasal delivery of tricyclic cannabinoids
TW200518760A (en) Triamcinolone acetonide and anecortave acetate formulations for injection
TW200602031A (en) Antiinflammatory and pain-relieving agent for external, use
EP1344526A4 (en) PROPHYLACTIC / THERAPEUTIC AGENTS FOR INFLAMMATORY RESPIRATORY DISEASES
PE20011005A1 (es) Combinaciones de un inhibidor de fosfodiesterasa 4 y un antiinflamatorio esteroideo para el tratamiento de las enfermedades pulmonares
MY136880A (en) Piperazinyl-or piperidinylamine-sulfamic acid amides as inhibitors of steroid sulfatase
TW200612962A (en) Estriol and estetrol prodrugs
BR0213634A (pt) Sistema de liberação de droga com ação retardada para um agente antiespasmódico
WO2004093852A3 (en) Use of steroid derivatives for the treatment of angiotensin ii related disease e.g. cardiovascular and proliferative disorders
EP1322315A4 (en) FORMULATIONS CONTAINING URSODESOXYCHOLIC ACID FOR REDUCING OR SUPPRESSING TOXICITY OF ENDOCRINE MODULATORS
YU87302A (sh) Inhibitori 11-beta-hidroksi steroidne dehidrogenaze, tip 1
TNSN06372A1 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
CA2295389A1 (en) Method of treatment of nausea, vomiting, and other disorders using estrogens

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
PNAN Change of the applicant name, address/residence

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, DE

PNAN Change of the applicant name, address/residence

Owner name: BAYER PHARMA AG, DE

PPPP Transfer of rights

Owner name: BAYER INTELLECTUAL PROPERTY GMBH, DE

B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20190228

Year of fee payment: 16

ODRP Renewal fee for the maintenance of a patent

Payment date: 20200225

Year of fee payment: 17

ODRP Renewal fee for the maintenance of a patent

Payment date: 20210312

Year of fee payment: 18

ODRP Renewal fee for the maintenance of a patent

Payment date: 20220314

Year of fee payment: 19

PPPP Transfer of rights

Owner name: GRUENENTHAL GMBH, DE

ODRP Renewal fee for the maintenance of a patent

Payment date: 20230201

Year of fee payment: 20

PB20 Patent expired after termination of 20 years

Effective date: 20240315